Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | GMNN | O75496 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9246291 | 1.00 | AOC3 (0.50) | AOC3MEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL9250397 | 1.00 | AOC3 (0.50) | AOC3MEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL13786083 | 0.89 | AOC3 (0.48) | AOC3MEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL13786104 | 0.89 | AOC3 (0.48) | AOC3MEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL24228682 | 0.87 | AOC3 (0.47) | AOC3MEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL31489731 | 0.82 | AOC3 (0.50) | AOC3MEN1KMT2AKDM4ESIGMAR1 | |
| SCHEMBL16340559 | 0.81 | AOC3 (0.53) | AOC3MEN1KMT2AKDM4ECYP3A4 | |
| SCHEMBL6481591 | 0.81 | AOC3 (0.53) | AOC3MEN1KMT2AKDM4ECYP3A4 | |
| SCHEMBL1155019 | 0.81 | AOC3 (0.53) | AOC3MEN1KMT2AKDM4ECYP3A4 | |
| SCHEMBL22473432 | 0.81 | TRPA1 (0.47) | AOC3MEN1KMT2AKDM4ESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098893-A1 | CYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DYSLIPIDEMIA, ATHEROSCLEROSIS AND DIABETES, PHARMACEUTICAL COMPOSITIONS AND PREPARATION PROCESS | MERCK PATENT GmbH (DE) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004011-A1 | CYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DYSLIPIDAEMIA, ATHEROSCLEROSIS AND DIABETES, PHARMACEUTICAL COMPOSITIONS AND PREPARATION PROCESS | MERCK PATENT GMBH (DE) | 2000-01-27 | — | — | WO | claimed |
| US-5395983-A | Process for producing 1-phenyl-1,3-propanediols having high optical purtiy | CHISSO CORPORATION (JP) | 1995-03-07 | — | — | US | claimed |
| CN-110914271-A | Bicyclic ketone compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-1556393-B1 | NOVEL CYCLIC PHOSPHATE DIESTERS OF 1,3-PROPANE-1-ARYL DIOLS AND THEIR USE IN PREPARING PRODRUGS | METABASIS THERAPEUTICS INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-7666855-B2 | 2′-C-methyl nucleoside derivatives | METABASIS THERAPEUTICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090131370-A1 | Novel Nucleoside Derivatives | METABASIS THERAPEUTICS , INC. (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MERCK SHARP & DOHME CORP. | 2009-05-07 | — | — | US | disclosed |
| US-7498320-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1915053-A2 | NOVEL 2'-C-METHYL AND 4'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1905778-A2 | Novel 2'-C-methyl nucleoside derivatives | Metabasis Therapeutics, Inc. (US) | 2008-04-02 | — | — | EP | disclosed |
| US-7148349-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1720556-A2 | NOVEL 2'-C-METHYL NUCLEOSIDE DERIVATIVES | Merck & Co., Inc. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005084192-A2 | NOVEL 2’-C-METHYL NUCLEOSIDE DERIVATIVES | MERCK & CO., INC. (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | METABASIS THERAPEUTICS, INC. | 2005-08-18 | — | — | US | disclosed |
| US-20040192651-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2004-09-30 | — | — | US | disclosed |
| EP-1098893-A1 | CYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DYSLIPIDEMIA, ATHEROSCLEROSIS AND DIABETES, PHARMACEUTICAL COMPOSITIONS AND PREPARATION PROCESS | MERCK PATENT GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004011-A1 | CYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DYSLIPIDAEMIA, ATHEROSCLEROSIS AND DIABETES, PHARMACEUTICAL COMPOSITIONS AND PREPARATION PROCESS | MERCK PATENT GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
| US-5395983-A | Process for producing 1-phenyl-1,3-propanediols having high optical purtiy | CHISSO CORPORATION (JP) | 1995-03-07 | — | — | US | disclosed |
| WO-1991017162-A1 | IMIDAZOPYRIDINE PAF ANTAGONISTS | PFIZER LIMITED (GB) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131370-A1 | Novel Nucleoside Derivatives | SLC29A1, SLC29A2, PNP | AOC3 3125/4885MEN1 2110/4885KMT2A 4301/4885 |
| US-20050182252-A1 | Hepatitis C viral infection; 2'-C-beta-methyl-7-deazaadenosine; trans-4-(aryl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes | MTAP, NT5C3B, ADAR | AOC3 305/4885MEN1 3629/4885KMT2A 3094/4885 |
| US-20090118223-A1 | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | MTAP, NT5C3B, NSUN2 | AOC3 3605/4885MEN1 3092/4885KMT2A 1072/4885 |
| US-20040192651-A1 | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | PNP, CYP2S1, CYP2F1 | AOC3 1811/4885MEN1 2145/4885KMT2A 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.